This Post Was Syndicated Under License Via QuoteMedia
ContraVir Pharmaceuticals (NASDAQ: CTRV), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral infection, has closed an underwritten public offering resulting in total gross proceeds of approximately $15.6 million. According to the update, the offered securities included (i) Class A units, at a combined price of $6.00 per unit, each consisting of one share of common stock and one warrant to purchase one share of common stock, and (ii) Class B units, at a combined price of $1,000 per unit, each consisting of one share of Series E convertible preferred stock, with a stated value of $1,000 per share, and convertible into 167 shares of common stock per share of Series E convertible preferred stock, and a warrant to purchase 167 shares of common stock. ROTH Capital Partners acted as lead placement agent for the offering.
To view the full press release, visit: http://nnw.fm/Q3lWn
About ContraVir Pharmaceuticals
ContraVir is a clinical state biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic hepatitis infection (“HBV,” “HCV,” “HDV”). The company’s lead drug candidate is CRV431, which reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH. Preclinical studies also have demonstrated antiviral activities towards HBV, HCV, and HDV through several mechanisms. These diverse therapeutic activities result from CRV431’s potent inhibition of cyclophilin enzymes, which are involved in many disease processes. Currently, in clinical phase development, CRV431 shows potential in the overall treatment of liver disease – from triggering events through to end-stage disease. For more information, visit the company’s website at www.ContraVir.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive instant SMS alerts, text STOCKS to 77948
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]
